ArticleJournal of medical biochemistry2025
Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The pathophysiological role of MiRNAs in heart failure.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the impact of traditional Chinese medicine treatment versus standard treatment on cardiac function metrics, serum inflammatory markers, and quality of life in patients with chronic heart failure (CHF). Methods: A total of 40 CHF patients were randomly assigned to either the observation group (TCM treatment) or the control group (standard Western therapy), with 20 patients in each group. Over a 3-month treatment period, primary outcomes including cardiac function indicators (ejection fraction [EF], cardiac output [CO], left ventricular end-diastolic pressure [LVEDP]), exercise tolerance (6-minute walk test [6MWT] results), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a]) were assessed. Secondary outcomes included the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and adverse reaction rates. Statistical analysis was performed using t-tests and chi-square tests, with significance set at P < 0.05. Results: After treatment, the observation group showed significantly greater improvements in EF (44.14% ± 4.95% vs. 40.15% ± 4.77%, P = 0.013), CO (4.62 ± 0.76 L/min vs. 4.10 ± 0.72 L/min, P = 0.032), LVEDP (18.76 ± 2.50 mmHg vs. 20.80 ± 2.64 mmHg, P = 0.016), and 6MWT results (526.84 ± 49.20 m vs. 432.75 ± 37.26 m, P < 0.001), compared to the control group. Inflammatory markers and MLHFQ scores were also significantly improved, while the adverse reaction rate was lower in the observation group (0.00% vs. 20.00%, P = 0.035). Conclusions: TCM as an adjunctive therapy demonstrates superior efficacy and safety compared to standard treatment for CHF, with significant improvements in cardiac function, exercise tolerance, and inflammatory markers. These findings provide quantitative evidence supporting the clinical application of TCM in CHF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.